期刊
ANNALS OF ONCOLOGY
卷 18, 期 4, 页码 752-760出版社
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdm003
关键词
epidermal growth factor receptor; gefitinib; gene copy number; non-small-cell lung cancer; protein expression
类别
资金
- NCI NIH HHS [2P30 CA 46934, CA 38926, CA 32102, P01 CA 58187, P50 CA070907] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [P30CA046934, P50CA058187, U10CA038926, U10CA032102, P50CA070907] Funding Source: NIH RePORTER
Background: Biological markers for optimal selection of patient to epidermal growth factor receptor (EGFR)-targeted therapies are not established in advanced non-small-cell lung cancer (NSCLC). Patients and methods: EGFR/HER2 gene copy number by FISH, EGFR protein and pAKT expression by immunohistochemistry (IHC) and EGFR and KRAS mutations were tested in 204 gefitinib-treated NSCLC patients. Results: Increased EGFR and HER2 gene copy number (FISH+), EGFR protein overexpression (IHC+), EGFR mutations and pAKT overexpression were all associated with significantly higher response rates (33%, 29%, 22%, 39% and 20% respectively). EGFR FISH+ (32%) and IHC+ (61%) correlated with improved survival, while EGFR mutations (27%), KRAS mutations (26%) and pAKT expression (69%) did not. In multivariate survival analysis EGFR FISH and IHC were independent predictive markers. EGFR FISH+/IHC+ patients (23%) had a median survival of 21 months versus 6 months for double-negative patients (30%). Conclusion: Combination of EGFR FISH and IHC is effective predictor for benefit from gefitinib. Patients with double-negative results are unlikely to benefit in western NSCLC populations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据